SCHEMBL6793899

SCHEMBL6793899

Cc1ccc(Sc2ccc(S(=O)(=O)N[C@H](C)C(=O)O)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 1/20 0.60
MMP9 P14780 5/20 0.57
MMP2 P08253 5/20 0.57
MMP13 P45452 4/20 0.57
MMP1 P03956 3/20 0.57
MMP3 P08254 2/20 0.57
MMP7 P09237 2/20 0.57
SLC1A3 P43003 1/20 0.54
SLC1A2 P43004 1/20 0.54
SLC1A1 P43005 1/20 0.54
TSHR P16473 2/20 0.50
HTT P42858 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CA9 Q16790 3/20 0.48
CA12 O43570 2/20 0.48
CA14 Q9ULX7 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
CA2 P00918 3/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL698908 0.91 ADAMTS4 (0.71) ADAMTS4MMP9MMP2MMP13MMP1
SCHEMBL698907 0.91 ADAMTS4 (0.71) ADAMTS4MMP9MMP2MMP13MMP1
SCHEMBL4975578 0.91 ADAMTS4 (0.71) ADAMTS4MMP9MMP2MMP13MMP1
SCHEMBL6798909 0.90 ADAMTS4 (0.70) ADAMTS4MMP9MMP2MMP13MMP1
Water SCHEMBL29881522 0.89 ADAMTS4 (0.69) ADAMTS4MMP9MMP2MMP13MMP1
SCHEMBL6800772 0.86 MMP2 (0.77) ADAMTS4MMP9MMP2MMP13MMP1
SCHEMBL6799581 0.86 TSHR (0.51) ADAMTS4MMP9MMP2MMP13MMP1
SCHEMBL8448539 0.82 ADAMTS4 (0.60) ADAMTS4MMP9MMP2MMP13MMP1
SCHEMBL8448545 0.82 ADAMTS4 (0.60) ADAMTS4MMP9MMP2MMP13MMP1
SCHEMBL8449004 0.82 MMP9 (0.75) ADAMTS4MMP9MMP2MMP13MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0977745-B1 THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS PHARMACIA CORP (US) 2004-12-01 EP disclosed
US-20040034071-A1 Thioaryl sulfonamide hydroxamic acid compounds PHARMACIA CORPORATION 2004-02-19 US disclosed
US-6087359-A A MATRIX METALLOPROTEASE ENZYME INHIBITOR PHARMACIA CORPORATION 2000-07-11 US disclosed
EP-0977745-A1 THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 2000-02-09 EP disclosed
WO-1998039313-A1 THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034071-A1 Thioaryl sulfonamide hydroxamic acid compounds MMP10, MMP1, MMP3 ADAMTS4 21/4885MMP9 8/4885MMP2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.